All enrolled clients who been given no less than 1 dose of zosuquidar or placebo all through induction were monitored for that prevalence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse situations were related to the period of extended and significant myelosuppression as is anticipated with induc